Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Viela planning BLA submission for inebilizumab in rare CNS disorder

Chris Lieu
January 4, 2019 7:07 PM UTC

Viela Bio Inc. (Gaithersburg, Md.) said it will submit a BLA to FDA this half for inebilizumab (MEDI-551) to treat neuromyelitis optica spectrum disorder (NMOSD) after the compound met the primary endpoint in the Phase II/III N-MOmentum trial in the indication. The company said worldwide regulatory submissions will quickly follow.

There are no approved therapies for NMOSD, a rare complement-mediated disorder of the CNS characterized by inflammatory lesions in the optic nerves and spinal cord...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Viela Bio Inc.

Viela Bio Inc.

BCIQ Target Profiles

CD19